QKI, as a representative marker of the tumor’s mesenchymal characters, may serve as a biomarker of statin sensitivity in colon cancer where the type II PAK inhibitors have shown their selectivity against mesenchymal-like subgroup [59]. This evidence concerns the gene QKI and malignant colon neoplasm.